Impact on Policy

Prescribing practices – and hence product opportunities – are increasingly constrained by post-regulatory controls. These take the form of clinical guidance issued by national government organisations or regional commissioners of care. In turn, these reflect the transnational guidelines developed by international professional associations. Non-medical interventions can also be subject to restrictions, either as a consequence of a restriction in funding or of service availability. All of these measures can impact patient access to all appropriate treatment options.

Gaining recognition of your product in the therapeutic hierarchy within these guidelines is necessary to optimise its market performance. HealthCare21 can help you with:

• Reviewing the evidence used in formulating guidelines and analysis of those involved in their development
• Benchmarking product positioning within guidelines and gap analysis
• Patient choice and access to care
• Market access and addressing stakeholder priorities
• Public affairs activities to lobby relevant stakeholders
• Generation of targeted communications programmes to increase awareness and understanding, speed decision-making and service delivery

go to case study